Pfiz­er projects mR­NA vac­cine sales will hov­er around $15B by 2030

Pfiz­er’s mR­NA vac­cines have been a high point for the com­pa­ny dur­ing the pan­dem­ic, and even with dwin­dling de­mand and gov­ern­ment re­sources, the phar­ma is pre­dict­ing $10 bil­lion to $15 bil­lion in an­nu­al rev­enue by 2030 for its mR­NA vac­cine port­fo­lio (in­clud­ing Comir­naty, flu, the com­bo of Covid-flu, and shin­gles).

While high­light­ing ma­jor 2022 vac­cine read­outs for its pen­tava­lent meningo­coc­cal vac­cine can­di­date, its RSV vac­cine can­di­date, Pre­vnar 20 (which Pfiz­er is hop­ing to co-ad­min­is­ter with its sea­son­al flu vac­cine), and more Comir­naty da­ta, CFO Dave Den­ton pro­ject­ed a 2023 core rev­enue growth of 7% to 9%, from $43.9 bil­lion in 2022 to $46.6 bil­lion in 2023, with a full pipeline of vac­cines for flu, Covid and flu, and shin­gles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.